AUTL Stock Overview
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Autolus Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.84 |
| 52 Week High | US$7.45 |
| 52 Week Low | US$2.74 |
| Beta | 2.04 |
| 11 Month Change | -36.04% |
| 3 Month Change | -28.82% |
| 1 Year Change | -36.61% |
| 33 Year Change | -55.69% |
| 5 Year Change | -80.13% |
| Change since IPO | -88.64% |
Recent News & Updates
Recent updates
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Nov 21Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Sep 06Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15
Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully
Dec 15Shareholder Returns
| AUTL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.6% | -6.5% | -1.0% |
| 1Y | -36.6% | 14.6% | 30.3% |
Return vs Industry: AUTL underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: AUTL underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| AUTL volatility | |
|---|---|
| AUTL Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AUTL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AUTL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 467 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc Fundamentals Summary
| AUTL fundamental statistics | |
|---|---|
| Market cap | US$745.14m |
| Earnings (TTM) | -US$270.23m |
| Revenue (TTM) | US$10.09m |
74.9x
P/S Ratio-2.8x
P/E RatioIs AUTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUTL income statement (TTM) | |
|---|---|
| Revenue | US$10.09m |
| Cost of Revenue | US$128.22m |
| Gross Profit | -US$118.12m |
| Other Expenses | US$152.10m |
| Earnings | -US$270.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | -1,170.59% |
| Net Profit Margin | -2,677.90% |
| Debt/Equity Ratio | 52.2% |
How did AUTL perform over the long term?
See historical performance and comparison